Aastrom achieves U.S. bone fracture milestone

By Elaine Rigoli

Tampa, Fla., June 29 - Aastrom Biosciences, Inc. said it has completed the last patient accrual and treatment in its U.S. phase 1/ 2 multi-center long bone fracture trial.

The company said completion of the cell therapy phase for all 36 patients enrolled in this trial represents a key milestone that supports Aastrom's business model to use its cell-based tissue repair cells (TRC) for tissue regeneration.

"This is an important company and clinical milestone that sets us well on our way in the evaluation of how well TRCs safely regenerate bone. If these data support our early feasibility study data, our TRC therapy should provide a new solution to a currently unmet need in the world of orthopedic medicine," vice president of global research and chief scientific officer Janet M. Hock said in a news release.

Aastrom, which develops products for the repair or regeneration of multiple human tissues, is based in Ann Arbor, Mich.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.